The FDA has granted new approvals for rheumatoid arthritis drugs Xeljanz and Rinvoq despite concerns over heart, cancer and blood clot side effects.
Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.
A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.
A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.
The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as…
Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.
The FDA may be delaying approval for the drug Rinvoq to be used as a psoriatic arthritis drug due to its close ties to Xeljanz, which has been linked to…